MOTS-c: what the research shows and how Belle prescribes it

What MOTS-c is

MOTS-c is a peptide your body already makes. It is a chain of 16 amino acids, and it is unusual for where it comes from. Most peptides the body produces are encoded in the nucleus. MOTS-c is encoded in the mitochondrial genome, inside the 12S ribosomal RNA gene, which is why researchers call it a mitochondrial derived peptide. It was first described in 2015 by a research group led by Changhan Lee, and it circulates in the blood of both humans and rodents.

MOTS-c is a prescription peptide at Belle. A licensed provider decides whether it fits your history after a medical intake, a US licensed compounding pharmacy prepares it to your prescription under USP sterility standards, and it ships with your name on the label. It is not an FDA approved drug. There is no approved brand product and no FDA reviewed label, so it is prescribed off label as a compounded medication, with your informed consent. Compounded medications are not FDA approved finished products. A licensed provider determines eligibility.

It is also not a stimulant. Caffeine and pre-workout products push you by masking the tiredness signal for a few hours, then fade. MOTS-c has been studied at a different level entirely: your metabolism and your mitochondria.

One recent regulatory fact belongs up front. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee reviewed MOTS-c as a candidate for the list of bulk substances that pharmacies may use in compounding, and voted 7 to 5, with two abstentions, to recommend adding it. FDA staff had proposed the opposite in their briefing document, because they did not identify any clinical study in which MOTS-c was given to people and lacked the data to assess the immunogenicity risk of an injected 16 amino acid peptide. The vote is a recommendation, not a rule: FDA is not bound by it, and any addition goes through a formal rulemaking process that typically runs eight to twelve months. No final determination had been posted as of September 19, 2026. For you, it means two things. Outside experts looked at the evidence and recommended a compounding pathway while the human trial record is still being built, which is why MOTS-c is prescribed under supervision rather than sold on a shelf. And the questions FDA staff raised about impurities and aggregation are exactly why the pharmacy preparing it matters as much as the molecule.

How it is thought to work

Mitochondria are the part of the cell that turns fuel into usable energy. MOTS-c acts as a messenger from the mitochondria to the rest of the cell, and its main target appears to be skeletal muscle.

Its central action is to activate AMPK, the enzyme that functions as the cell energy sensor. Exercise activates AMPK too, which is why researchers describe MOTS-c as an exercise mimetic. In laboratory research, AMPK activation by MOTS-c promoted glucose uptake and fatty acid oxidation in muscle.

Under metabolic stress, MOTS-c does something few molecules can do: it moves into the nucleus. There, in an AMPK dependent manner, it regulates a broad set of genes, including genes with antioxidant response elements that help the cell adapt to stress. These are described mechanisms under study, not a promise of any result.

What the research shows

Three tiers of peptide evidence are worth naming: FDA approved for a specific indication, an FDA studied analog prescribed for a related use, and compounded and prescribed off label. MOTS-c sits in the third tier. Here is the map, laid out the way a provider would lay it out across a desk: what is known, what the research suggests, and what is still being learned.

What is known

The existence of MOTS-c, and its involvement in cellular metabolism, are established in the scientific literature. It is present in human circulation, and in humans exercise increases MOTS-c in skeletal muscle and in the bloodstream. A 2025 study found that serum MOTS-c levels in marathon runners and sedentary adults tracked closely with aerobic exercise capacity. Circulating levels decline with age.

Two observational studies looked at metabolic status. A 2018 study of 10 lean and 10 obese adults found plasma MOTS-c similar in both groups, with a correlation to insulin resistance that held in the lean participants. A 2025 study of 85 adults found no difference between people with obesity and people at a normal weight, with age and insulin resistance as the main predictors of the level. These studies measure MOTS-c. None of them gave it to anyone.

What the research suggests

Researchers have studied MOTS-c in metabolism, insulin sensitivity and exercise, largely in preclinical and animal models, and the work is peer reviewed. In the original 2015 study, MOTS-c treatment in mice prevented age dependent and high fat diet induced insulin resistance, as well as diet induced obesity. A 2021 study reported that MOTS-c enhanced physical performance in young, middle aged and old mice, and that treatment started late in life increased physical capacity and healthspan.

FDA reviewed this literature in 2026 and described its limits plainly: rodent and cell models only, no assessment of dose response, and molecular targets not yet known. A promising result in animals is a reason to study a compound in people. It is not itself proof in people, which is why it is prescribed with monitoring.

What is still being learned

No published trial has given MOTS-c to people and measured an outcome. FDA searched for one in 2026 and did not find it. The human data is still catching up to the clinical use, and individual responses vary, which is why your provider sets realistic expectations with you.

The remainder of the evidence base is accumulated prescribing experience. That experience is not nothing. It has shaped clinical intuition in the practitioners who use these compounds, and it is different in kind from a controlled trial. A 2026 review in sports medicine put the balance fairly: many unapproved peptides show favorable metabolic and tissue outcomes in animal models, while rigorous human safety data remain scarce.

Dr. Taylor on MOTS-c

MOTS-c activates the same AMPK pathway that exercise does, which means improved insulin sensitivity, better glucose metabolism, and enhanced mitochondrial function. I use it for patients who are metabolically compromised or physically limited and need to jumpstart their cellular metabolism. It is not a replacement for exercise, but it can amplify the benefits for patients who are starting from a deficit. Dr. Patrick Taylor, MD, Chief Medical Officer at Belle

Who explores it, and who should wait

The patients who ask about MOTS-c tend to fall into a few groups, listed roughly in the order the evidence supports them: adults with reduced insulin sensitivity or metabolic dysfunction, where the animal data and the mechanism are strongest; adults who are physically limited and want to support cellular metabolism while they rebuild activity; adults who already exercise and want to complement it, not replace it; and adults noticing an age related decline in energy, a pattern that matches the age related decline in MOTS-c levels.

Not everyone is a candidate. A licensed provider weighs what is known against your goals and your history, and stays involved.

Who should talk to a provider first

• Pregnancy or breastfeeding
• Anyone taking a GLP-1 medication such as tirzepatide or semaglutide, so the two are considered together
• Active cancer or a history of malignancy
• Type 1 diabetes
• Other medications that lower blood sugar, where adding a peptide that affects glucose handling needs supervision
• Known mitochondrial disease
• Athletes who compete under anti-doping rules: MOTS-c appears on the World Anti-Doping Agency prohibited list

Side effects reported in clinical use are generally mild: injection site irritation, mild headache (rare), and temporary fatigue during initial dosing. There is no established evidence of long term harm at this time, and no established evidence of long term safety either, because those studies have not been done. That is not a reason to avoid the conversation. It is a reason to have a provider monitoring your response rather than dosing from a spreadsheet.

How it is taken

MOTS-c is given as a small subcutaneous injection you give yourself at home, similar to other at-home injectables. The route matters: peptides are broken down quickly in the digestive tract and in blood, so injection is how the molecule reaches circulation intact long enough to act. Your kit includes step by step instructions, and nurse support is available if you want a hand getting started.

Dosing is not one size fits all. Your provider sets your dose and schedule after your medical intake, and adjusts it as your protocol progresses.

Where the real risk is

For most people considering MOTS-c, the largest risk is not the molecule. It is the vial.

FDA noted in 2026 that compounded products containing MOTS-c appear to be offered online in the United States. Some of it carries a label that reads for research use only. That label is not marketing filler. It is the legal line that lets a vendor sell a chemical without the oversight that applies to medicine. If a vial arrives with no prescriber, no pharmacy label and no patient name on it, you are the quality control step.

The impurity and aggregation questions FDA raised are the exact questions a licensed compounding pharmacy answers with sterile preparation, testing and a named pharmacist responsible for the batch. The higher price of a prescription is buying the whole chain: the provider review, the prescription, the compounding, the testing, and the fact that someone is responsible for what ends up in the vial.

How Belle prescribes MOTS-c

Belle offers MOTS-c as a prescription compounded peptide for energy and metabolic health. It begins with a short online screening reviewed by a licensed provider, who looks at your health history, your goals and your current medications, then builds a protocol around you or tells you MOTS-c is not the right fit. If it is prescribed, a US licensed compounding pharmacy prepares it to your prescription and ships it to you with a patient specific label. A prescription is never guaranteed. That uncertainty is a feature of doing this responsibly, not a flaw in the process.

Belle publishes the shape of the protocol: it runs in 10 week cycles, with medication for eight weeks followed by a two week reset that is part of the prescribed protocol, and the pharmacy processes refills on that cycle until you cancel. Belle is cash pay, so no insurance or referral is involved.

Belle also prescribes BPC-157, GHK-Cu and tesamorelin as compounded peptides, each after its own provider review.

If a treatment is not appropriate for you, the answer is no, and that is the point of the review.

Many patients report improved energy and exercise tolerance within two to four weeks of starting MOTS-c. Metabolic and insulin sensitivity changes are typically noted later, often by four to eight weeks. Those are patient reports rather than trial endpoints. Timelines and outcomes vary by individual, and your provider will monitor your progress and adjust your protocol as needed.

Nothing here is medical advice. Decisions about your own care belong with a licensed provider who knows your history.